Serum Gal-9 levels were also positively correlated with sTIM-3 levels and NAFLD severity gradings in our RA patients, supporting the findings that the Gal-9/TIM-3 signaling contributed to NAFLD in a murine model (24). This evidence concerns the gene LGALS9 and metabolic dysfunction-associated steatotic liver disease.